Frankfurt am Main, April 23, 2014 -- Moody's Investors Service has today placed on review for downgrade the A1 long-term ratings of GlaxoSmithKline plc (GSK) and its rated subsidiaries. Concurrently, Moody's has affirmed the (P)P-1/P-1 short-term ratings of GSK and affected subsidiaries.

Vollständigen Artikel bei Moodys lesen